TCG Crossover Management LLC Buys 137,380 Shares of Kodiak Sciences Inc. (NASDAQ:KOD)

TCG Crossover Management LLC boosted its stake in shares of Kodiak Sciences Inc. (NASDAQ:KOD - Free Report) by 13.6% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 1,145,538 shares of the company's stock after acquiring an additional 137,380 shares during the period. Kodiak Sciences accounts for 1.1% of TCG Crossover Management LLC's portfolio, making the stock its 29th largest holding. TCG Crossover Management LLC owned approximately 2.18% of Kodiak Sciences worth $11,398,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds also recently bought and sold shares of KOD. Barclays PLC boosted its position in shares of Kodiak Sciences by 65.5% during the 3rd quarter. Barclays PLC now owns 79,658 shares of the company's stock valued at $208,000 after acquiring an additional 31,527 shares during the last quarter. JPMorgan Chase & Co. raised its stake in Kodiak Sciences by 220.9% during the third quarter. JPMorgan Chase & Co. now owns 44,648 shares of the company's stock valued at $117,000 after purchasing an additional 30,735 shares in the last quarter. State Street Corp grew its stake in shares of Kodiak Sciences by 1.8% in the 3rd quarter. State Street Corp now owns 816,634 shares of the company's stock worth $2,131,000 after buying an additional 14,711 shares in the last quarter. Peapod Lane Capital LLC bought a new stake in shares of Kodiak Sciences in the 4th quarter worth about $1,660,000. Finally, Geode Capital Management LLC raised its position in shares of Kodiak Sciences by 1.7% during the 3rd quarter. Geode Capital Management LLC now owns 768,740 shares of the company's stock valued at $2,007,000 after buying an additional 12,783 shares in the last quarter. 89.06% of the stock is currently owned by institutional investors.

Kodiak Sciences Stock Performance

KOD stock traded up $0.31 during mid-day trading on Friday, reaching $4.80. 615,630 shares of the stock traded hands, compared to its average volume of 344,196. Kodiak Sciences Inc. has a one year low of $1.92 and a one year high of $11.60. The stock has a market capitalization of $253.21 million, a PE ratio of -1.32 and a beta of 2.40. The business has a 50-day moving average price of $3.27 and a two-hundred day moving average price of $5.46.

Kodiak Sciences (NASDAQ:KOD - Get Free Report) last issued its quarterly earnings results on Thursday, March 27th. The company reported ($0.84) EPS for the quarter, beating the consensus estimate of ($0.90) by $0.06. On average, equities analysts expect that Kodiak Sciences Inc. will post -3.45 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reiterated a "neutral" rating and issued a $3.00 price target on shares of Kodiak Sciences in a research report on Monday, March 31st.

About Kodiak Sciences

Kodiak Sciences Inc, a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.